ZYBERNO
Stock Report
Updated Aug 21, 2026

Regentis Biomaterials Ltd. (RGNT)

Healthcare • NYSE

$2.00

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
Regentis Biomaterials Ltd. (RGNT) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.09x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-2,903.3%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Regentis Biomaterials Ltd. (RGNT) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:2.00
Market Cap:$1.13M

Valuation Multiples (2)

P/B Ratio:0.24x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:-$5.05M

Price Action & Momentum (1)

% of 52-Week High:12.9%
B. Profitability Assessment

Return Metrics (3)

Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.57x
Quick Ratio:2.57x
Cash Ratio:2.57x

Leverage Analysis (3)

Debt To Equity Ttm:0.09x
Debt-to-Equity Ratio:0.09x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-88.20x
Times Interest Earned:-88.20

Capital Structure (4)

Working Capital:4,504,000.00
Cash And Cash Equivalents:7,378,000.00
Long Term Debt:$0.00
Net Debt:-$6.18M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$6.97M

Bottom Line Performance (3)

-$13.65M
Income Before Tax:$13.65M
Ebitda Ttm:-6,968,000.00

Operating Expenses (5)

Operating Expenses:0.00
R And D Expense:0.00
Sga Expense:6,637,000.00
Income Tax Expense:$0.00
Interest Expense:79,000.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$7.62M
Current Assets:$7.38M
Ppe Net:0.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:2,874,000.00
Current Liabilities:2,874,000.00
Long Term Debt:$0.00
Short Term Debt:$1.20M

Equity & Capital (3)

Equity:$4.74M
Retained Earnings:-$55.79M
Common Stock:22,500,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:1,393,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:7,042,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$1.38M$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:$8.52M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$862.00K
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$24.08

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$2.43

Book Value & Capital (2)

Book Value Per Share:$8.37
Cash Per Share:13.02

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:RGNT
Company Name:Regentis Biomaterials Ltd.
Sector:Healthcare
Industry:Medical Devices
Exchange:NYSE
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:566.74K
Shares Outstanding Basic:566.74K
Shares Outstanding Diluted:566.74K

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-21 13:19:15 UTC
Data Timestamp:2026-08-21T13:19:15.324838
Scroll to Top